For Jin Seok, nurturing the plants and growing a garden has parallels with growing a business. “First, we need to nurture people to provide what they need, care for them and encourage their growth. Patience is required to allow the time that they need to develop and grow. As a plant sometimes needs, we ensure routine care, monitoring & support to anticipate and prevent any sign of ‘disease’ and promote strong development. And of course, we enjoy and celebrate at the end when all the potential is deployed, and the achievements realized”, he says. Jin Seok’s analogy reflects the culture at Novasep.
This has helped the company position itself as a leading provider of services in the field of molecule production and purification for the life science industries. An unrivalled pool of specialized and differentiating technologies coupled with fully committed teams are its main differentiators. “Novasep has more than 30 years’ experience in the production of molecules for pharmaceutical innovators, and the key to Novasep’s success still remains its people,” mentions Jin Seok.
"Technology has always been a strong differentiating asset for Novasep, and we continue to build on it"
Novasep works to continually support its employees to improve their skills through global training programs. To ensure the same, the company has an in-house ‘Novasep University', focused on four core areas, namely, the Novasep Business Academy, which helps employees learn management and training strategies, the Novasep College, including Novasep Sales Academy founded to help employees develop the business acumen of its sales and business team and Novasep Management School to provide all managers with a common leadership culture. Finally, the Novasep Continuous Improvement School provides focused training on operational excellence, principles, and methodologies.
Created in 1996, Novasep expanded into API Synthesis in 2003 with the purchase of Seripharm, a specialist HPAPI site located in Le Mans, France, which today is a leading player in the manufacture of Antibody Drug Conjugates (ADCs).
The power of our network lies in its ability to manage several steps of chemistry through different sites to provide flexible capacity and increase security of supply
The company has a long and successful history with the US, having provided manufacturing services for APIs to US pharmaceutical innovators for more than 30 years. "We were one of the first European CDMOs to establish partnerships with US clients and still produce for US-based historical customers whether for their active commercial products or for their molecules in development," states Jin Seok.
What also differentiates Novasep is its culture of innovation. “It’s one of the company’s values, embodied by the existence of a dedicated innovation department whose work spans from the deployment of new technologies such as Flow Chemistry to the digitization of our practices such as the application of data mining to better characterize processes," informs Jin Seok. Novasep’s innovation team is composed of members integrated directly at its sites, interacting daily with operations and external partners.
Novasep remains close to its customers, listening to them and understanding their challenges and needs to provide customized solutions.
Recent events have further underlined customers’ need to secure supply chains and ensure business continuity in a growing market and with flexible capacities. “The power of our network lies in its ability to manage several steps of chemistry through different sites to provide flexible capacity and increase security of supply” says Jin Seok.
Novasep has deployed an investment strategy for many years, investing continuously to upgrade its capacities and broaden the flexibility and productivity to satisfy its clients.
Recently, Novasep has announced the development of its ADC offer through reinforcement of its HPAPI capacities. The company is also upgrading and increasing the flexibility of its API manufacturing sites. “Novasep is currently working on strengthening its assets in the US, motivated in part by the increasing desire of drug companies in the country to secure domestic supply,” concludes Jin Seok.